BioCentury
ARTICLE | Emerging Company Profile

Selective Regeneration

How Surrozen is targeting specific Wnt receptors to regenerate select tissues

July 20, 2018 8:26 PM UTC

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members of the highly interrelated Wnt receptor family. The biotech is focusing first on bone and liver regeneration.

Wnts, or wingless-type MMTV integration site proteins, are a class of secreted molecules that help drive embryonic development and, later in life, regenerate tissue after injury. ...